- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05925738
Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
Positron Emission Tomography/ Computed Tomography (PET/CT) Based Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Guizhou
-
Zunyi, Guizhou, China
- Recruiting
- Affiliated Hospital of Zunyi Medical University
-
Contact:
- Yongxiang Song, Dr
- Phone Number: 15505177258
- Email: zhong961008@163.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Recruiting
- The First Affiliated Hospital Of Nanchang University
-
Contact:
- Bentong Yu, Dr
- Phone Number: 021-65115006
- Email: 1151697503@qq.com
-
-
Zhejiang
-
Ningbo, Zhejiang, China
- Recruiting
- Ningbo HwaMei Hospital
-
Contact:
- Minglei Yang, Dr
- Phone Number: 021-65115006
- Email: almondjj@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
(1) Participants scheduled for surgery for radiological finding of pulmonary lesions from the preoperative thin-section CT scans; (2) Pathological confirmation of primary NSCLC; (3) Age ranging from 20-75 years; (4) Obtained written informed consent.
Exclusion Criteria:
(1) Multiple lung lesions; (2) Poor quality of PET-CT images; (3) Participants with incomplete clinical information; (4) Participants who have received neoadjuvant therapy.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the receiver operating characteristic curve
Time Frame: 2023.5.1-2023.10.31
|
The area under the receiver operating characteristic curve (ROC) of the deep learning model in predicting the presence or absence of the aggressive histological pattern.
The aggressive histological pattern includes spread through air space (STAS), visceral pleural invasion (VPI), and lymphovascular invasion (LVI).
And the model will output all predictive values (presence or absence) of the three kinds of aggressive histological patterns.
|
2023.5.1-2023.10.31
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity
Time Frame: 2023.5.1-2023.10.31
|
The sensitivity of the deep learning model in predicting the presence or absence of the aggressive histological pattern.
The aggressive histological pattern includes spread through air space (STAS), visceral pleural invasion (VPI), and lymphovascular invasion (LVI).
And the model will output all predictive values (presence or absence) of the three kinds of aggressive histological patterns.
|
2023.5.1-2023.10.31
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity
Time Frame: 2023.5.1-2023.10.31
|
The specificity of the deep learning model in predicting the presence or absence of the aggressive histological pattern.
The aggressive histological pattern includes spread through air space (STAS), visceral pleural invasion (VPI), and lymphovascular invasion (LVI).
And the model will output all predictive values (presence or absence) of the three kinds of aggressive histological patterns.
|
2023.5.1-2023.10.31
|
Positive predictive value
Time Frame: 2023.5.1-2023.10.31
|
The positive predictive value of the deep learning model in predicting the presence or absence of the aggressive histological pattern.
The aggressive histological pattern includes spread through air space (STAS), visceral pleural invasion (VPI), and lymphovascular invasion (LVI).
And the model will output all predictive values (presence or absence) of the three kinds of aggressive histological patterns.
|
2023.5.1-2023.10.31
|
Negative predictive value
Time Frame: 2023.5.1-2023.10.31
|
The negative predictive value of the deep learning model in predicting the presence or absence of the aggressive histological pattern.
The aggressive histological pattern includes spread through air space (STAS), visceral pleural invasion (VPI), and lymphovascular invasion (LVI).
And the model will output all predictive values (presence or absence) of the three kinds of aggressive histological patterns.
|
2023.5.1-2023.10.31
|
Accuracy
Time Frame: 2023.5.1-2023.10.31
|
The accuracy of the deep learning model in predicting the presence or absence of the aggressive histological pattern.
The aggressive histological pattern includes spread through air space (STAS), visceral pleural invasion (VPI), and lymphovascular invasion (LVI).
And the model will output all predictive values (presence or absence) of the three kinds of aggressive histological patterns.
|
2023.5.1-2023.10.31
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DLAHP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on PET/CT-based Deep Learning Signature
-
Shanghai Pulmonary Hospital, Shanghai, ChinaZunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...RecruitingNon-small Cell Lung CancerChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaZunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...RecruitingNon-small Cell Lung Cancer | Neoadjuvant Chemoimmunotherapy | Complete Pathological ResponseChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaZunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...RecruitingLung Adenocarcinoma | Whole Slide Image | Novel Grading SystemChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaZunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...RecruitingLung Adenocarcinoma | Radiomics | Grading SystemChina
-
Chang ChenZunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated... and other collaboratorsRecruiting
-
First Affiliated Hospital of Chongqing Medical...Recruiting
-
Asan Medical CenterUnknownCavernous Sinus Invasion by Pituitary AdenomaKorea, Republic of
-
Seoul National University HospitalKorea Health Industry Development Institute; Dong-A University; Inha University... and other collaboratorsNot yet recruitingHospital Rapid Response Team | Hospital Medical Emergency Team
-
Jiangxi Provincial Cancer HospitalGuangdong Provincial People's HospitalRecruitingLung Cancer | Artificial IntelligenceChina
-
University Hospital, BonnPhilips HealthcareCompletedProstate Cancer | Multiparametric MRIGermany